TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

PHASE2TerminatedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 1, 2011

Study Completion Date

December 1, 2011

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Otelixizumab

Infusion

Trial Locations (17)

1655

GSK Investigational Site, Worcester

20037

GSK Investigational Site, Washington D.C.

21201

GSK Investigational Site, Baltimore

32207

GSK Investigational Site, Jacksonville

33781

GSK Investigational Site, Pinellas Park

35294

GSK Investigational Site, Birmingham

39501

GSK Investigational Site, Gulfport

44060

GSK Investigational Site, Mentor

49048

GSK Investigational Site, Kalamazoo

55455

GSK Investigational Site, Minneapolis

57701

GSK Investigational Site, Rapid City

60637

GSK Investigational Site, Chicago

68131

GSK Investigational Site, Omaha

80045

GSK Investigational Site, Aurora

94598

GSK Investigational Site, Walnut Creek

78229-4801

GSK Investigational Site, San Antonio

M4G 3E8

GSK Investigational Site, Toronto

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

GlaxoSmithKline

INDUSTRY